These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 26416473)

  • 1. Clindamycin and rifampicin: No bull's eye without a target.
    Béraud G; Le Moal G; Sury S; Venisse N
    J Infect; 2016 Jan; 72(1):120-1. PubMed ID: 26416473
    [No Abstract]   [Full Text] [Related]  

  • 2. Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination.
    Bernard A; Kermarrec G; Parize P; Caruba T; Bouvet A; Mainardi JL; Sabatier B; Nich C
    J Infect; 2015 Aug; 71(2):200-6. PubMed ID: 25936632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of a combined oral clindamycin?rifampicin regimen for therapy of staphylococcal osteoarticular infections.
    Czekaj J; Dinh A; Moldovan A; Vaudaux P; Gras G; Hoffmeyer P; Lew D; Bernard L; Uçkay I
    Scand J Infect Dis; 2011 Dec; 43(11-12):962-7. PubMed ID: 21916775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections.
    Hoyo I; Martínez-Pastor J; Garcia-Ramiro S; Climent C; Brunet M; Cuesta M; Mensa J; Soriano A
    Scand J Infect Dis; 2012 Jul; 44(7):548-50. PubMed ID: 22385321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infections.
    Curis E; Pestre V; Jullien V; Eyrolle L; Archambeau D; Morand P; Gatin L; Karoubi M; Pinar N; Dumaine V; Nguyen Van JC; Babinet A; Anract P; Salmon D
    Infection; 2015 Aug; 43(4):473-81. PubMed ID: 25837442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clindamycin-rifampin combination therapy for staphylococcal periprosthetic joint infections: a retrospective observational study.
    Leijtens B; Elbers JBW; Sturm PD; Kullberg BJ; Schreurs BW
    BMC Infect Dis; 2017 May; 17(1):321. PubMed ID: 28464821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of phagocytic cells with antibiotics: uptake and intracellular killing activity.
    Seger RA; Mühlebach T
    Acta Paediatr Hung; 1988-1989; 29(1-2):153-8. PubMed ID: 3076459
    [No Abstract]   [Full Text] [Related]  

  • 8. Why rifampin (rifampicin) is a key component in the antibiotic treatment of hidradenitis suppurativa: a review of rifampin's effects on bacteria, bacterial biofilms, and the human immune system.
    Scheinfeld N
    Dermatol Online J; 2016 Jun; 22(6):. PubMed ID: 27617596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Elution kinetics and antimicrobial effects of gentamicin- and clindamycin-loaded bone cements in vitro].
    Schiefer UR; Heiss C; Dingeldein E; Wenisch S; Schnettler R; Kilian O
    Z Orthop Unfall; 2008; 146(1):92-8. PubMed ID: 18324589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting effects of antibiotic combinations using MICs determined at pharmacokinetically derived concentration ratios: in vitro model studies with linezolid- and rifampicin-exposed Staphylococcus aureus.
    Golikova MV; Strukova EN; Portnoy YA; Dovzhenko SA; Kobrin MB; Zinner SH; Firsov AA
    J Chemother; 2017 Oct; 29(5):267-273. PubMed ID: 28192070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent menstrual toxic shock syndrome despite discontinuation of tampon use: is menstrual toxic shock syndrome really caused by tampons?
    Dixit S; Fischer G; Wittekind C
    Australas J Dermatol; 2013 Nov; 54(4):283-6. PubMed ID: 22897229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reply to "Rifampin and clindamycin are safe long-term".
    Sayed C; Alikhan A A
    J Am Acad Dermatol; 2023 Jan; 88(1):e33. PubMed ID: 31568805
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis.
    Tsaganos T; Skiadas I; Koutoukas P; Adamis T; Baxevanos N; Tzepi I; Pelekanou A; Giamarellos-Bourboulis EJ; Giamarellou H; Kanellakopoulou K
    J Antimicrob Chemother; 2008 Aug; 62(2):381-3. PubMed ID: 18445576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model.
    Baldoni D; Furustrand Tafin U; Aeppli S; Angevaare E; Oliva A; Haschke M; Zimmerli W; Trampuz A
    Int J Antimicrob Agents; 2013 Sep; 42(3):220-5. PubMed ID: 23880168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections, with focus on doxycycline.
    Hamad T; Hellmark B; Nilsdotter-Augustinsson Å; Söderquist B
    APMIS; 2015 Dec; 123(12):1055-60. PubMed ID: 26547372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of vancomycin serum trough concentrations and outcomes in meticillin-resistant Staphylococcus aureus bacteraemia.
    Arshad S; Shoyinka A; Chen A; Jacobsen G; Zervos M
    Int J Antimicrob Agents; 2012 Nov; 40(5):474-5. PubMed ID: 22883416
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates.
    Vidaillac C; Parra-Ruiz J; Winterfield P; Rybak MJ
    Int J Antimicrob Agents; 2011 Oct; 38(4):301-6. PubMed ID: 21764263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of severe staphylococcal infections. Failure of rifampicin in combination therapy. 4 cases].
    Garaud JJ; Regnier B; Lassoued K; Pangon B; Leport C
    Presse Med; 1985 May; 14(18):1013-6. PubMed ID: 3158945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and dynamic study of levofloxacin and rifampicin in bone and joint infections.
    Guillaume M; Garraffo R; Bensalem M; Janssen C; Bland S; Gaillat J; Bru JP
    Med Mal Infect; 2012 Sep; 42(9):414-20. PubMed ID: 22944286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The bactericidal power of antibiotic combinations. Application in the treatment of osteo-articular infections due to Staphylococcus aureus (author's transl)].
    Sirot J; Lopitaux R; Cluzel R; Bussière JL; Rampon S
    Nouv Presse Med; 1978 Oct; 7(36):3217-22. PubMed ID: 733486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.